Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States.The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
